Genetic Markers of Suicidal Ideation Emerging During Citalopram Treatment of Major Depression
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Suicidal ideation is an uncommon symptom than can emerge during antidepressant treatment. The biological basis of treatment-emergent suicidal ideation is unknown. Genetic markers may shed light on the causes of treatment-emergent suicidal ideation and help identify individuals at high risk who may benefit from closer monitoring, alternative treatments, or specialty care. METHOD: A clinically representative cohort of outpatients with major depressive disorder who enrolled in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial were treated with citalopram under a standard protocol for up to 14 weeks. DNA samples from 1,915 participants were genotyped for 768 single-nucleotide polymorphisms in 68 candidate genes. Allele and genotype frequencies were compared between the 120 participants who developed treatment-emergent suicidal ideation and those who did not. RESULTS: Two markers were significantly associated with treatment-emergent suicidal ideation in this sample (marker rs4825476, p=0.0000784, odds ratio=1.94; permutation p=0.01; marker rs2518224, p=0.0000243, odds ratio=8.23; permutation p=0.003). These markers reside within the genes GRIA3 and GRIK2, respectively, both of which encode ionotropic glutamate receptors. CONCLUSIONS: Markers within GRIK2 and GRIA3 were associated with treatment-emergent suicidal ideation during citalopram therapy. If replicated, these findings may shed light on the biological basis of this potentially dangerous adverse event and help identify patients at increased risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Environment and Disease: Association or Causation?
Hill, A. B. (1965) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576505800503 · Cited by 6,974
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citationPurcell, S., Cherny, S. S., & Sham, P. C. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.1.149 · Cited by 2,057
Pedigree disequilibrium tests for multilocus haplotypes.
Dudbridge, F. (2003) · Genetic Epidemiology · doi:10.1002/gepi.10252 · Cited by 1,135
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076 · cited 1×
“Ascertainment and evaluation for the STAR*D study have been detailed elsewhere (10, 11).”
Self-citationTRIVEDI, M. H., RUSH, A. J., IBRAHIM, H. M., CARMODY, T. J., BIGGS, M. M., SUPPES, T., CRISMON, M. L., SHORES-WILSON, K., TOPRAC, M. G., DENNEHY, E. B., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291703001107 · Cited by 968
Self-citationRush, A. J., Carmody, T., & Reimitz, P. (2000) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.79 · Cited by 427
Self-citationSuicide Risk During Antidepressant Treatment
Simon, G. E., Savarino, J., Operskalski, B., & Wang, P. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.41 · Cited by 424 · cited 1×
“Evidence suggests that the risk of suicide attempt is higher in depressed persons before the prescription of antidepressants than afterward (35).”
BackgroundRush, A. J., Bernstein, I. H., Trivedi, M. H., Carmody, T. J., Wisniewski, S., Mundt, J. C., Shores-Wilson, K., Biggs, M. M., Woo, A., Nierenberg, A. A., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.022 · Cited by 385 · cited 3×
“Consistent with previous definitions of treatment-emergent suicidal ideation, we used the " thoughts of death or suicide " question (item 12) from the 16-item Quick Inventory of Depressive Symptomatology—Self-Report (QIDS-SR), a reliable and well-validated measure of symptom severity that has been shown to correlate w…”
MethodInfluentialSelf-citation
Cited by
Neurobiological and Systemic Effects of Chronic Stress
McEwen, B. S. (2017) · Chronic Stress · doi:10.1177/2470547017692328 · Cited by 1,059
Major depressive disorder: new clinical, neurobiological, and treatment perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60602-8 · Cited by 894
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564
Candidate endophenotypes for genetic studies of suicidal behavior
Mann, J. J., Arango, V. A., Avenevoli, S., Brent, D. A., Champagne, F. A., Clayton, P., Currier, D., Dougherty, D. M., Haghighi, F., Hodge, S. E., et al. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.021 · Cited by 398
Self-citationSequeira, A., Mamdani, F., Ernst, C., Vawter, M. P., Bunney, W. E., Lebel, V., Rehal, S., Klempan, T., Gratton, A., Benkelfat, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006585 · Cited by 388
“[86] that genetic variation at the GRIA3 gene seems to be associated with suicidal ideation during citalopram therapy and suggests that expression changes in this gene may also confer susceptibility to suicide and suicidal ideation in antidepressant treated patients.”
Personalized Medicine for Depression: Can We Match Patients With Treatments?
Simon, G. E., & Perlis, R. H. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09111680 · Cited by 365
Machine learning in major depression: from classification to treatment outcome prediction
Gao, S., Calhoun, V. D., & Sui, J. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13048 · Cited by 370
Recognizing resilience: Learning from the effects of stress on the brain
McEwen, B. S., Gray, J. D., & Nasca, C. (2015) · Neurobiology of Stress · doi:10.1016/j.ynstr.2014.09.001 · Cited by 292
“Clearly, the impact of sex and sex differences has undergone a revolution and much more is to come (Cahill, 2006; Laje et al., 2007; McEwen, 2009; McEwen and Lasley, 2005; Meites, 1992), including insights into X and Y chromosome contributions to brain sex differences (Carruth et al.”
BackgroundKantrowitz, J., Citrome, L., & Javitt, D. (2009) · CNS Drugs · doi:10.2165/00023210-200923080-00001 · Cited by 260
Genomic and epigenomic mechanisms of glucocorticoids in the brain
Gray, J. D., Kogan, J. F., Marrocco, J., & McEwen, B. S. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.97 · Cited by 242
Glutamatergic Modulators: The Future of Treating Mood Disorders?
Zarate, C., Machado-Vieira, R., Henter, I., Ibrahim, L., Diazgranados, N., & Salvadore, G. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.511059 · Cited by 228
Shaltiel, G., Maeng, S., Malkesman, O., Pearson, B., Schloesser, R. J., Tragon, T., Rogawski, M., Gasior, M., Luckenbaugh, D., Chen, G., et al. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.20 · Cited by 173
Shared decision making in mental health: prospects for personalized medicine
Drake, R. E., Cimpean, D., & Torrey, W. C. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.4/redrake · Cited by 173
Mirkovic, B., Laurent, C., Podlipski, M.-A., Frebourg, T., Cohen, D., & Gerardin, P. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00158 · Cited by 168
“(139) reported two other glutamatergic genes (GRIA3 and GRIK2) in relation to TESI.”
BackgroundBrent, D., Melhem, N., Ferrell, R., Emslie, G., Wagner, K. D., Ryan, N., Vitiello, B., Birmaher, B., Mayes, T., Zelazny, J., et al. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09040576 · Cited by 138
Meyer, R. E., Salzman, C., Youngstrom, E. A., Clayton, P. J., Goodwin, F. K., Mann, J. J., Alphs, L. D., Broich, K., Goodman, W. K., Greden, J. F., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10cs06070blu · Cited by 129
Pharmacogenetics of antidepressants
Crisafulli, C., Fabbri, C., Porcelli, S., Drago, A., Spina, E., De Ronchi, D., & Serretti, A. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00006 · Cited by 113
Myung, W., Han, C. E., Fava, M., Mischoulon, D., Papakostas, G. I., Heo, J.-Y., Kim, K. W., Kim, S. T., Kim, D. J. H., Kim, D. K., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.110 · Cited by 101
From synapse to nucleus: Novel targets for treating depression
Covington, H. E., Vialou, V., & Nestler, E. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.12.004 · Cited by 98
Novel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
“Interestingly, the STAR*D study as well as the Munich Antidepressant Response Signature (MARS) project both described an association between treatment-emergent suicidal ideation and the glutamate system via the involvement of the GRIK3 and GRIK2 genes (Laje et al., 2007, Menke et al., 2008).”
MethodAn update on the role of glutamate in the pathophysiology of depression
Mitchell, N. D., & Baker, G. B. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01529.x · Cited by 91
Pharmacogenetics Studies in STAR*D: Strengths, Limitations, and Results
Laje, G., Perlis, R. H., Rush, A. J., & McMahon, F. J. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.11.1446 · Cited by 89
Self-citationHorton, S. E., Hughes, J. L., King, J. D., Kennard, B. D., Westers, N. J., Mayes, T. L., & Stewart, S. M. (2016) · Journal of Abnormal Child Psychology · doi:10.1007/s10802-015-0109-5 · Cited by 73
Reverse translational strategies for developing animal models of bipolar disorder
Malkesman, O., Austin, D. R., Chen, G., & Manji, H. K. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.001628 · Cited by 70
“…phenotype that may be associated with BD (Laje et al., 2007); notably, the same gene conferred sensitivity to treatmentemergent suicidal ideation in a large, collaborative study of individuals with mood disorders [Sequenced treatment alternatives to relieve depression (STAR*D)] (Laje et al., 2007).”
BackgroundSelf-citationEscitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults
Garnock-Jones, K. P., & McCormack, P. L. (2010) · CNS Drugs · doi:10.2165/11204760-000000000-00000 · Cited by 66
Limon, A., Mamdani, F., Hjelm, B. E., Vawter, M. P., & Sequeira, A. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.04.010 · Cited by 63
Perroud, N., Uher, R., Marusic, A., Rietschel, M., Mors, O., Henigsberg, N., Hauser, J., Maier, W., Souery, D., Placentino, A., et al. (2009) · BMC Medicine · doi:10.1186/1741-7015-7-60 · Cited by 57
“Firstly, most of these studies used only one scale to measure suicidal ideation: a more sensitive selfreport questionnaire, risking false positives [9,12] or a more specific clinician-rated scale [10,11,13] risking false negatives.”
InfluentialGenome-wide association studies of suicidal behaviors: a review
Sokolowski, M., Wasserman, J., & Wasserman, D. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.08.006 · Cited by 48
Regulation of kainate receptor subunit mRNA by stress and corticosteroids in the rat hippocampus
Hunter, R. G., Bellani, R., Bloss, E., Costa, A., McCarthy, K., & McEwen, B. S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004328 · Cited by 40
“Polymorphisms in the KA1 receptor have been associated with response to the anti-depressant citalopram and GluR6 has been associated with suicidal ideation during treatment with the same drug [6,7].”
Background
Metadata
- Authors
- Laje, G., Paddock, S., Manji, H., Rush, A. J., Wilson, A. F., Charney, D., & McMahon, F. J.
- Venue
- American Journal of Psychiatry
- Published
- 2007-10
- Volume
- 164
- Issue
- 10
- Pages
- 1530-1538
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2123738251
- Cited by
- 213
- References
- 10
- FWCI
- 18.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.